Decaf coffee linked to better survival in colorectal cancer patients, study finds

A study of nearly 1,100 colorectal cancer patients has found that what you drink after diagnosis may matter more than doctors have previously understood—but the answer is messier than a simple yes or no. Researchers tracking the Multiethnic Cohort Study examined coffee consumption and survival outcomes among people living with colorectal cancer, separating total coffee intake, caffeinated coffee, and decaffeinated coffee to see which, if any, influenced how long patients lived. The results suggest that decaffeinated coffee may offer a protective effect, while the relationship between caffeine and survival is more complicated than expected.

Colorectal cancer remains the second leading cause of cancer death in the United States. Previous research has hinted that coffee consumption might influence survival outcomes—laboratory studies show coffee has anti-inflammatory and antioxidant properties—but most existing work has lacked racial and ethnic diversity. This study, published in Cancer Causes & Control, deliberately recruited a varied population: 42 percent Japanese American, 21 percent White, 16 percent Latino, 14 percent Black, and 7 percent Native Hawaiian. The researchers tracked 1,098 people diagnosed with colorectal cancer, collecting detailed information about their coffee drinking habits at enrollment between 1993 and 1996, then again roughly five years after diagnosis, between 2003 and 2008. Over the follow-up period, 628 participants died, including 107 from colorectal cancer itself.

The headline finding breaks down into layers. When the researchers looked at total coffee intake and caffeinated coffee alone, neither showed a significant link to survival across the entire cohort. But decaffeinated coffee told a different story. People who drank more decaffeinated coffee had lower rates of all-cause mortality—meaning they lived longer, from any cause. This association held even after researchers controlled for caffeine intake from other sources, suggesting something in decaf coffee beyond the absence of caffeine was doing the work. The picture shifted again when researchers examined the highest quartile of caffeine intake from all sources—coffee, tea, diet soda, regular soda. Those in the top quarter for caffeine consumption showed lower risks of both all-cause mortality and colorectal cancer-specific mortality.

When the researchers broke the data down by race and ethnicity, patterns emerged that were not entirely consistent. Among White participants, higher intake of both caffeinated and total coffee was associated with lower colorectal cancer-specific mortality. Higher decaffeinated coffee intake was linked to lower all-cause mortality only among White individuals. Among Native Hawaiians, higher caffeine and total coffee intake correlated with reduced all-cause mortality risk. But the researchers were cautious: the analyses did not provide clear evidence that these associations truly differed meaningfully by race and ethnicity. In Native Hawaiian participants, too few colorectal cancer deaths occurred to model cancer-specific mortality at all.

Coffee consumption itself varied by race and ethnicity. About 23 percent of White participants drank at least two cups of coffee daily, compared with 21 percent of Native Hawaiians, 19 percent of Japanese Americans, 19 percent of Latino participants, and 14 percent of Black participants. People who drank more coffee also tended to exercise more, consume more calories, and smoke more—factors that complicate any simple reading of the data. The researchers accounted for these differences statistically, but the underlying reality remains: coffee drinkers are not a random sample of the population.

The study carries real limitations that the authors did not minimize. Because this was an observational study, it cannot prove that coffee caused better survival—only that coffee consumption and survival were associated. A survival bias shaped the results: 735 people diagnosed with colorectal cancer died before they could complete the follow-up dietary questionnaire, meaning the study only captured data from people who lived long enough to answer questions about their habits years after diagnosis. Small numbers in some racial and ethnic groups made subgroup analyses unreliable. Few participants reported very high coffee intake, limiting what the researchers could say about extreme consumption.

One additional finding offered a hint at something more dynamic: when researchers looked at whether people changed their coffee drinking habits after diagnosis, an increase in coffee intake from before to after diagnosis was associated with lower all-cause mortality when analyzed as a continuous measure. But when they broke this into categories, the association disappeared. The researchers cautioned that the continuous result may have been driven by statistical outliers rather than a true pattern.

What emerges is not a clear directive but an invitation to further investigation. Decaffeinated coffee showed the most consistent protective signal, independent of caffeine. The highest levels of caffeine intake correlated with better survival outcomes. But total coffee intake alone predicted nothing. The variation by race and ethnicity suggests that coffee's effects may not be universal—a finding that demands replication and explanation. For now, the study adds coffee to a growing list of factors that may influence colorectal cancer survival, while leaving the mechanism and the magnitude of that influence still to be determined.